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Autologous haematopoietic stem cell transplantation (AHSCT) is increasingly used
to treat people with multiple sclerosis (MS). Supported by an evolving evidence
base, AHSCT can suppress active inflammation in the central nervous system and
induce long-term changes in immune cell populations, thereby stabilizing, and, in
some cases, reversing disability in carefully selected MS patients. However, AHSCT is
an intensive chemotherapy-based procedure associated with intrinsic risks, including
profound cytopenia, infection, and organ toxicity, accompanied by an on-going degree
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of immuno-compromise and general deconditioning, which can be associated with
a transient increase in functional impairment in the early stages after transplantation.
Although international guidelines and recommendations have been published for clinical
and technical aspects of AHSCT in MS, there has been no detailed appraisal of the
rehabilitation needed following treatment nor any specific guidelines as to how this is
best delivered by hospital and community-based therapists and wider multidisciplinary
teams in order to maximize functional recovery and quality of life. These expert consensus
guidelines aim to address this unmet need by summarizing the evidence-base for AHSCT
in MS and providing recommendations for current rehabilitation practice along with
identifying areas for future research and development.
Keywords: autoimmune diseases, autologous haematopoietic stem cell transplantation, neurological diseases,
multiple sclerosis, rehabilitation, physical therapy, exercise
INTRODUCTION
Multiple Sclerosis
Multiple Sclerosis (MS) is an acquired chronic immune-mediated
inflammatory disease of the central nervous system (CNS) and
is the commonest cause of non-traumatic disability in adults of
working age (1, 2).
Approximately 85% of people with MS present with a
relapsing remitting course (RRMS) characterized by distinct
episodes of new or worsening neurological dysfunction (relapses)
followed by complete or partial recovery (remission) (3). In the
majority of cases, patients transition into a secondary progressive
phase (SPMS) 10–25 years after the disease onset, accumulating
progressive disability (4). A minority of patients (10–15%)
present with a progressive disease course from the onset of
disease, described as primary progressive MS (PPMS) (4).
Clinical presentation varies dependent on the site of lesions
within the CNS. Clinical features may include abnormalities
of muscle strength, sensation, balance, coordination, vision,
cognition, speech, swallowing, bladder, bowel, and sexual
function as well as tremor, pain, fatigue, heat sensitivity, and
changes in mood and personality (5). MS can be highly disabling
with considerable personal, social, and economic consequences
(6, 7).
MEDICAL MANAGEMENT OF MULTIPLE
SCLEROSIS
Currently, there is no known cure for MS. Medical treatment
aims to modify the course of the disease process and control
symptoms as they develop (8). In RRMS, treatment is aimed
at reducing permanent damage to the CNS by decreasing
inflammation and preventing relapses (8). There are now 15
licensed disease-modifying therapies (DMTs), which aim to
suppress inflammation and prevent the progressive phase of
disease (9). Steroids are frequently used to manage relapses
Abbreviations: AD, Autoimmune Disease; ADL, Activities of Daily
Living; ADWP, Autoimmune Disease Working Party; AHSCT, Autologous
Haematopoietic Stem Cell Transplantation; MDT, Multi-Disciplinary Team; MS,
Multiple Sclerosis; OMs, Outcome Measures.
in the acute setting, but have no beneficial long-term effect.
The treatment options for patients with SPMS and PPMS are
very limited.
DMTs have various levels of efficacy but many patients
respond poorly and continue to accumulate disability (10). There
is also a risk of immuno-compromise and other toxicities.
In recent years increasing numbers of patients with MS have
been treated with autologous HSCT (11–13). Specific EBMT
guidelines have been published to assist with patient selection,
advice about transplant protocols, and supportive care (14).
AHSCT AND MULTIPLE SCLEROSIS
In recent years an increasing evidence base and published
professional guidelines have supported more widespread use of
AHSCT as a treatment option in patients with highly active
RRMS. MS is now the fastest growing indication for AHSCT
across Europe (15).
AHSCT provides a “one-off” treatment as opposed to DMTs,
which generally require on-going administration (7, 16). AHSCT,
however is an intensive chemotherapy-based procedure that
can result in deconditioning and which may add further to
functional impairment, at least temporarily (17). AHSCT and its
associated short- and long-term risks require counseling, detailed
workup and an admission to specialized HSCT facilities (18). The
provision of a coordinated care plan derived jointly by transplant
hematologists, MS neurologists, and other allied healthcare
professionals is essential throughout the procedure (19).
Although AHSCT is not thought to be directly associated
with repair or regeneration of damaged myelin or nerve fibers,
previous studies have demonstrated reversal of disability in some
patients following treatment which could be explained by the
prolonged suppression of inflammation and physiological CNS
repair (19). Secondary benefits of AHSCT include reduced fatigue
and improved energy reserves in contrast to profound fatigue,
which is commonly associated with active inflammation (20).
At present there are no studies to confirm whether neuro-
rehabilitation may promote recovery following AHSCT (21), but
this may be a reasonable extrapolation from standard neuro-
rehabilitation practice. AHSCT has the capacity to halt the
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inflammatory process for an extended period of time, which may
allow the CNS to acquire the capacity to repair and re-organize
the damaged areas. Neuro-rehabilitation can contribute to this.
NEURO-REHABILITATION IN MS
Outcomes for individuals with MS could be maximized through
rehabilitation; both by optimizing a patient’s physical fitness
and by guiding and stimulating neuroplasticity. In MS, evidence
suggests that neuroplasticity can play a role in limiting the clinical
impact of damage (22). Task orientated interventions can result
in the reorganizing or restoration of altered patterns of brain
activity andmay induce clinically meaningful re-myelination and
plasticity changes (23). InMS, maladaptive plasticity can occur in
the CNS following neuronal injury (23), highlighting the need for
specialist therapy teams to guide rehabilitation intervention.
With AHSCT, there is a rapid and prolonged suppression
of CNS inflammation associated with a sustained interval
free of immunosuppressive treatments; therefore, the early
administration of a neuro-rehabilitation program represents a
unique opportunity to maximize its effect, possibly in association
with axonal repair.
Similar to the medical management for MS, rehabilitation
intervention is determined by the symptoms and clinical
presentation for each patient and therefore a full clinical
assessment is essential with the rehabilitation being goal
directed and person centered (24, 25). This should be
multi-disciplinary with involvement from neurologists,
specialist nurses, rehabilitation specialists, physiotherapists,
occupational therapists, speech and language therapists, and
neuro-psychologists. Where possible, the rehabilitation must
involve self-management and where possible family and carers
to ensure a 24 h approach.
THE UNMET NEED: GUIDELINES AND
RECOMMENDATIONS FOR
REHABILITATION OF PATIENTS
UNDERGOING AHSCT FOR MS
Currently, there is no established rehabilitation pathway for
patients with MS either before or after AHSCT. Although pre-
habilitation and rehabilitation have been explored in malignant
hematological diseases where AHSCT is routinely used (26),
there is very limited evidence in relation to AHSCT in MS.
In addition, there is no consensus as to how rehabilitation
should be delivered and provision will vary from country to
country. Now that there is a significant demand across health
services in many countries for AHSCT in patients with MS
(14), addressing this unmet need has become an urgent matter.
Therapists need clear guidelines to advise when they should start
rehabilitation, to what intensity, how to address the potential
complications associated with the AHSCT procedure and how to
tailor rehabilitation programs to suit each individual’s symptoms
and goals. Rehabilitation plans need to factor in patients’
initial presentation and their positive and negative response
to AHSCT particularly if they become systemically unwell and
deconditioned during the treatment period.
AIMS AND PROCESS FOR GUIDELINES
AND RECOMMENDATIONS
The following guidelines and recommendations have been
established by consensus to support therapists with the
rehabilitation of patients with MS undergoing AHSCT with the
goal of optimizing management and overall outcome.
Methodology
Following approval by the processes of the EBMT Autoimmune
Diseases Working Party (ADWP), an authorship group was
convened from clinicians from relevant professional groups
active in or associated with the ADWP and Nurses Group (NG)
of the European Society for Blood and Marrow Transplantation
(EBMT) with experience in AHSCT for neurological ADs
as well as patient consumer representation via the EBMT
Patient Advocacy Committee. As such, this group included
therapists, hematologists, neurologists, specialist nurses, and
patient representation, with access to patients with MS who
had undergone AHSCT. An important point is that several
areas of specialism have collaborated to share expertise in
respective areas.
In the absence of specific studies or guidelines for
rehabilitation before or after HSCT for MS, based on knowledge
within the authorship group and literature searching, the aim
was to produce an expert consensus as a starting point. A
systematic review was considered to be premature and therefore
was not undertaken. Whilst the structure of the guideline and
recommendations broadly considered the principles of the
AGREE process (27), this was not a systematic review nor did
it address specific health question or adhere to the AGREE or
similar process. The output was therefore in line with other
EBMT guidelines and recommendations, including a recent
“White Paper Report” (26) developed to guide rehabilitation in
patients who have or are due to receive AHSCT which focused
on allogeneic HSCT and graft-versus-host disease.
The target readership primarily includes specialist therapists
directly involved in planning rehabilitation for patients with MS
undergoing AHSCT as well as clinical teams and their members
involved in the planning and delivery of AHSCT. As such the
guidelines are written in a technical style for the target readership
of health professionals, and, although they are not intended as a
primary resource for patient information, they should be made
accessible to them via their health professionals. These guidelines
cover adults, young people, and children. They are intended
to be holistic aiming to address physical rehabilitation as well
as cognitive, communication, and psychosocial factors. Specific
evidence in the area of rehabilitation in AHSCT for MS is very
limited, and therefore all recommendations are consensus and
based on agreed best practice within the group, whilst the need
for future systematic research in specific areas is recognized.
The aim of these guidelines and recommendations is to
suggest a pathway for rehabilitation, recognizing the challenges
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that patients face at each stage. A further aim was to generate
questions for future research in this field. We have divided the
rehabilitation process into four phases:
– Phase 1: Assessment and pre-habilitation 4 weeks before
starting treatment,
– Phase 2: Acute rehabilitation,
– Phase 3: Sub-acute rehabilitation, and
– Phase 4: Community rehabilitation including vocational
rehabilitation.
Each phase of the pathway has a different emphasis but each
treatment plan must still be tailored to the individual and will
change depending on the stage of a patient’s rehabilitation. These
guidelines therefore outline the assessment process and propose
outcome measures and standardized assessment tools as well as
guidance on therapeutic interventions.
SELECTION CRITERIA FOR AHSCT FOR
PATIENTS WITH MS
Patients with MS being considered or offered AHSCT should
meet the criteria suggested in current EBMT guidelines and
recommendations and further updates, and treatment should
be approved by an appropriately constituted multi-disciplinary
team (MDT) (14).
THE MULTIDISCIPLINARY TEAM (MDT)
In line with EBMT recommendations, care should be provided
with a co-ordinated multidisciplinary approach by a team
responsible for initial assessment of suitability for AHSCT, and an
extended team, who facilitate referral, assessment, and delivery of
rehabilitation throughout the four phases of the pathway.
The MDT membership should include:
• Neurologist(s) with an interest in MS
• Hematologist(s) with an interest in HSCT
• Specialist MS nurse(s)
• Specialist HSCT nurse(s)
• Rehabilitation specialist(s)
• Specialist therapists (acute, sub-acute and community based)
including physiotherapists, occupational therapists, speech
and language therapists
• Neuropsychologists and counselors
• Dieticians
• Pain management specialists
• Infectious disease specialists
• Other specialist nurses including continence and tissue
viability nurses, late effects nurses
• GPs and district nursing teams.
AHSCT – THE PROCESS
For detailed general and MS specific literature on AHSCT,
please refer to EBMT guidelines for AHSCT in MS and
neurological diseases (14, 17, 28, 29) and recent reviews,
which cover the transplant process itself and its us
in MS.
The process is summarized in Figure 1 and as follows:
1. Pre-transplant workup, including wash out of DMTs Patients
should be reviewed by both MS neurologists and transplant
Hematologists who are experienced in using AHSCT in this
context. Patients are initially assessed and provided with
extensive counseling to ensure that they are familiar with the
benefits and risks of AHSCT (18, 30). Both short- and long-
term risks including the effect on reproductive function and
other late effects need to be considered (31). The individual is
usually taken off their DMT at variable time points prior to the
stem cell mobilization, dependent on the specifice DMT (14).
2. Peripheral blood stem cell [PBSC] mobilization and
leukapheresis In the weeks to months prior to transplant, the
patient undergoes a stem cell mobilization procedure, which
allows stem cells to be procured for later transplantation (29).
3. Conditioning regimen Depending on the protocol,
the patient is generally hospitalized from the start
of the intensive cytotoxic “conditioning” regimen,
which usually includes a combination of high-dose
chemotherapy and antibody-based therapy [such as anti-
thymocyte globulin (ATG)] which results in ablation of
haematopoietic and immune cells throughout the body
(17). Usually a central venous line is inserted to facilitate
administration of cytotoxic drugs and transfusions. The
line may occasionally remain in situ beyond the AHSCT
procedure and its presence may need consideration when
planning rehabilitation.
4. The “transplant” The cryopreserved stem cells are thawed
and infused through the central venous line with
close monitoring of the patient in case of reaction toe
the infusion.
5. Post-transplant care Following stem cell infusion, the patient
remains in hospital for a period of close monitoring,
supportive care for side effects of treatment, and isolation
from potential sources of infection while awaiting engraftment
of the haematopoietic system, usually defined as the recovery
of a neutrophil count of 109/L for three days (17), which in
most cases occurs 10–14 days following the infusion of the
stem cells.
Patients are usually discharged from hospital within 4 weeks,
although this depends on their baseline condition and tolerance
of AHSCT. Potential early side effects include fever, infection,
and sepsis in association with leukopenia, other cytopenias
(anemia and thrombocytopenia) requiring blood product
transfusions, and a range of other organ toxicities (alopecia,
mucositis, diarrhea, vomiting, renal, and fluid balance issues and
serum sickness). Worsening of existing neurological symptoms
can occur often in the context of fever, drug reactions, and
infection (17). Neurological deterioration in response to fever
is known as the Uhthoff phenomenon, and, whilst the effect
on patients during AHSCT is usually short lived and reversible,
some evidence suggests the potential for prolonged deleterious
effect on neurological function (32). Thus, a proactive approach
is appropriate during AHSCT including prompt administration
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FIGURE 1 | Schematic overview of the AHSCT process Step one: Mobilization of AHSCs from the bone marrow by leukapheresis and cryopreserved until required.
Step two: Conditioning regimen using high dose chemotherapy for ablation of the immune system. Step 3: Re-infusion of autologous haematopoeitic stem cells
(AHSC). Engraftment of bone marrow takes 10–14 days. Step 4: Post-transplant care and supportive therapy.
of antibiotics and steroid treatment to prevent or minimize the
duration of fever (32).
Secondary complications include deconditioning, reduced
caloric intake due to nausea and mucositis and limited activity
in the immediate post-transplant period (32). Prolonged bed
rest and isolation during AHSCT may also lead to pressure
sores, thromboembolic risks, changes in spasticity and posture,
acquired urinary or bowel dysfunction, bone loss, vitamin D
deficiency, low mood, and fatigue (17).
Long-term effects include risks of infertility (31), autoimmune
dysfunction including thyroid abnormalities and autoimmune
cytopenias, endocrine, and other organ impairment and
secondary malignancies (28).
REHABILITATION WITHIN THE AHSCT
PATHWAY
Utilizing a biopsychosocial model, rehabilitation aims to
optimize a patients’ health, functional independence and well-
being, comprising a comprehensive programme covering the
physical, cognitive, psychological, and social aspects of their
care. Previous recommendations have advocated the need for
physical therapy before and after HSCT to promote recovery of
functional capacity and improve quality of life (26). These were
aimed at a wide range of hematological conditions and did not
include the special considerations for neurological conditions
including MS.
The paucity of evidence in the field of rehabilitation means
that it is not possible to make firm recommendations. However, a
summary of the basis for AHSCT alongside consensus guidance
is presented to support therapists and clinicians caring for these
patients to optimize collaborative care and identify areas for
future development.
In these guidelines, rehabilitation for patients with AHSCT
is delivered over 4 distinct phases during the pathway as
detailed above and in Figure 2. Whilst traditionally rehabilitative
interventions are delivered during and after treatment, these
guidelines recommend an initial “pre-habilitation” phase in line
with current evidence in the field of cancer rehabilitation. Pre-
habilitation would occur before “beginning of acute treatment
and would include physical and psychological assessments that
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FIGURE 2 | Rehabilitation Pathway for MS patients undergoing AHSCT (AHSCT, Autologous Haematopoietic Stem cell Transplantation; OMs, Outcome Measures;
Rehab, Rehabilitation).
establish a baseline functional level, identifies impairments, and
provides targeted interventions that improve a patient’s health
to reduce the incidence and the severity of current and future
impairments” (33). We suggest that pre-habilitation is a potential
solution to address the needs of these MS patient to improve
their outcomes.
In general terms, patients who receive enhanced
therapy whilst in acute care go home sooner (34).
Rehabilitation in sub-acute and long-term follow up
phases may further improve functional outcomes and
reduce the burden of long-term care costs associated with
dependency but further research is needed to determine the
benefits (21, 34).
REHABILITATION MODEL
Effective rehabilitation is holistic, multi-disciplinary, goal
directed, patient centered, and, where possible, evidence
based, as recommended in the various international
rehabilitation guidelines for patients with MS including the
NICE guidelines (35), the Cochrane review of 2019 (25)
and European Multiple Sclerosis Platform Rehabilitation
Recommendations (36) to name a few. It is essential that
the rehabilitation is adapted to patients’ changing needs as
they progress.
A series of reliable and validated outcome measures (OMs)
should be recorded at key points throughout the patient’s journey
tomonitor any change in key domains within the biopsychosocial
model of care as outlined by the World Health Organization’s
International Classification of Functioning, Disability and
Health (37).
The Assessment
Patients should undergo a detailed assessment (25, 35) at the
start of each phase of rehabilitation not only looking at a
patient physically but also their cognition, psychology, speech,
function, and the utilization of standardized assessments tools
and outcome measures where possible is encouraged. This will
be patient specific depending on their presentation and will be
phase specific.
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Standardized Assessment Tools and
Outcome Measures (OMs)
There are no tools or OMs specifically available for use for
patients with MS receiving AHSCT and future research into
this area is needed. Whilst these guidelines suggest a spectrum
of tools and OMs, these are not exhaustive and must be used
based on a patient’s presentation and their phase of rehabilitation.
For example, a patient may not be able to mobilize acutely
in the initial days following their transplant, and a 10m walk
test will only be appropriate when they progress and start
to mobilize.
To assess someone’s cognitive function, there are a number
of standardized assessment tools. For example, the Minimal
Assessment of Cognitive Function in MS (MACFIMS), and
the Montreal Cognitive Assessment (MoCA) have been shown
to be a valuable screening tool for MS patients (38, 39).
The Brief International Cognitive Assessment for Multiple
Sclerosis (BICAMS) was specifically designed with MS patients
in mind (40). Further examples of cognitive assessments include
the Loewenstein Occupational Therapy Cognitive Assessment
(LOCTA) (41), the Rivermead Memory Team (42), the Behavior
Assessment of the Dysexecutive Syndrome (43) and the
TEA—Test of Everyday Attention which are not specific to
MS (44).
For some patients, an assessment of their cognition through
function may be more beneficial. For speech therapy, there are
assessments for dysarthria for example the Frenchay Dysarthria
Assessment (FDA-2) (45) and for language, the Mount Wilga
High Level Language Assessment but neither are exclusive to the
MS population.
Much like the assessment tools, a series of reliable and
validated outcome measures (OMs) should be recorded at key
points throughout the transplantation treatment to monitor any
change in key domains within the biopsychosocial model of care
as outlined by the World Health Organization’s International
Classification of Functioning, Disability and Health (37). In
accordance with our recommendations, OMs should be used
at the start and end of each phase and when there is
significant change.
The National Multiple Sclerosis Society suggested a number
of measures (46) but Cohen et al. described a clinical decision
making process when selecting outcomemeasures (47). However,
to date, no research has been conducted to recommend specific
OMs for the MS population undergoing AHSCT. Therefore,
our recommendations cover those OM with evidence base
specifically in patients with MS. The Academy of Physical
Therapy in 2012 (48–50) suggested the following OMs in patients
with MS:
– 10m walk test
– Berg balance
– Modified fatigue impact scale
– Rivermead Mobility index
– MS QOL 54 measure
– Dynamic gait index
– Activities of daily living (ADL)
– Nine hole peg test.
REHABILITATION DURING PHASE 1:
ASSESSMENT AND PRE-HABILITATION−4
WEEKS TO START OF TREATMENT
Assessment
Prior to the transplant, it is recommended that baseline level
of impairment function and participation is ascertained through
a formal MDT assessment process. This should include a
full medical and physical assessment, including a medication
and social history A physical assessment should include
joint range of movement, muscle strength, length and tone,
balance, sensation, cerebellar signs, proprioception, movement
analysis, and endurance including respiratory function. The
patient’s cognition, swallowing, communication, nutritional
status, functional independence, and endurance should also be
assessed including determining how they transfer, mobilize, and
complete personal activities of daily living including washing,
dressing, feeding as well as their ability to do domestic tasks. A
range of standardized outcome measures normally form part of
the full assessment (see above).
Risk Assessment
It is important that any risk factors for potential deterioration
are identified. These may include fatigue, existing muscle
weakness or spasticity, reduced respiratory function, poor cough,
contractures, pressure sores, postural changes, urinary tract
infections and other infections, constipation, deconditioning,
compromised nutrition, and pain (26). As well as MS,
there may be co-morbidities that heighten the risk of these
potential complications.
Advice and Information
In Phase 1, the key focus is optimizing the patients’ physical,
social, and emotional functioning and well-being prior to them
undergoing AHSCT. Patients should be given individualized
advice and education to help them self-manage their
rehabilitation and prevent risks occurring. Advice leaflets
provide guidance on exercise, nutrition, and any necessary
lifestyle changes supporting a self-care and self-management
paradigm. If appropriate, carers and family members should also
be provided with advice and education to support the individual.
Specialist consultationmay be necessary/beneficial in some cases.
The Rehabilitation— “Pre-habilitation”
During phase 1, “Pre-habilitation,” can be provided as part of an
intensive community rehabilitation package or in an outpatient
setting. Residential rehabilitation may be required based on a
patient’s presentation. Pre-habilitation during this phase will be
patient centered based on a full assessment.
The aims of this stage are not only to enhance neuromuscular
systems and respiratory function but also to reduce the risk of
secondary complications. The following should be considered,
as appropriate:
– Breathing exercises and the use of respiratory adjuncts to
optimize respiratory function (51).
– Cardiovascular exercise. The evidence suggests that adults
withMS should engage in at least 30min of moderate intensity
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aerobic activity twice a week as well as strength training of
major muscle groups biweekly to optimize fitness (52). High
impact weight bearing exercises such as hopping, jumping,
combination exercises should also be considered if appropriate
as these have a positive impact on bone mass density (53). Pre-
transplant fitness can have a positive influence on recovery
(34). Access to appropriate gym equipment such as a cross-
trainer or static bike to enhance physical fitness may be
required. Care should be taken to ensure that the level of
exercise prescribed reflects the patient’s clinical presentation,
over-exertion could have a negative impact. The extent
of cardiovascular exercise and the patient’s ability to use
equipment will depend on their presentation and pre-morbid
level of function (54). Stairs or mobility may provide adequate
cardiovascular exercise at this stage.
– Strengthening and stretching programmes (55)
– Spasticity management (35)
– The use of neuro-technologies (56)
– Cognitive rehabilitation (35, 57, 58),
– Nutrition (35),
– Relaxation (36),
– Fatigue management (35),
– Pain management (35)
– Providing strategies to accomplish transfers and ADL (34)
and
– The provision of equipment including aids and orthotics
as appropriate.
All activities should be underpinned by a self-management
approach, where possible.
REHABILITATION DURING PHASE 2:
ACUTE REHABILITATION
Rehabilitation during this phase will be goal directed and
patient centered helping prevent secondary problems through
gentle mobilization. As such it aims to prevent cachexia and
optimize respiratory function. At this stage, the provision of
appropriate levels of exercise will be influenced by platelet count
and fatigue. In most cases platelet count will have recovered
by day +15 post-transplant although secondary immune
thrombocytopenia may occur in 5–7% of patients later on.
Mental health and well-being should be monitored throughout
this phase.
The main consideration for rehabilitation at phase 2 is the
individual’s immunity. The immune system begins to recover
around 2 weeks after infusion of the blood stem cells, during
which patients are likely to remain in hospital for close
monitoring and continuation of supportive treatment such as
antibiotics. Even with neutrophil recovery, the immune system
remains suppressed for several months. Any infections may
adversely affect patients physically and cognitively (17). Infection
control measures should be observed. As this patient group is
at risk of urinary dysfunction, there may be a risk of urosepsis
and rarely haemorrhagic cystitis and patients may require urinary
catheterisation (59).
Contraindications and Precautions to
Rehabilitation
Following AHSCT, patients invariably have cytopenias increasing
the risk of infection and bleeding. At this time, physical function
does need to be monitored so it is essential that skilled therapists
are involved in guiding rehabilitation.
Thrombocytopenia is sometimes considered a
contraindication to exercise and therefore platelet count
should be monitored and exercise prescribed as appropriate. A
previous consensus publication (26) has proposed the following
scale for general HSCT patients.
– <20× 109/L contraindication to exercise
– 20–30× 109/L—gentle non-resistant exercises
– 30–50× 109/L—minimal resistance (0.5–1 kg exercises)
– 50–150× 109/L—progressive resisted exercises
– >150× 109/L—no restrictions.
Assessment
Following the transplant and when medically appropriate,
the individual is reassessed in line with the WHO ICF (37)
by an appropriate MDT. Any potential areas of risk should
be communicated to the specialist transplant therapy team
before discharge. Any deterioration must be identified. If a
patient’s swallow has worsened, a bedside videofluoroscopy may
be required.
Advice and Information for
Self-Management
Following the assessment, carers including nursing staff and
family should be provided with manual handling advice
to facilitate safe transfers and mobility whilst encouraging
independence, provided there is no negative impact. They should
also be provided with any positioning or seating guidance to
optimize respiratory function and posture and to aid spasticity
management if this continues to be a problem. These patients will
also need advice on minimizing the risk of infections, which may
include breathing exercises and be on an appropriate diet.
Rehabilitation
The following should be assessed by an MDT as appropriate:
• Posture—in lying, sitting, standing, walking
• Seating
• Provision of any specialist equipment required
• Respiratory status





• Personal activities of daily living and participation.
For specific symptom management, please see Multiple Sclerosis
in Adults: Management (35). The following should be considered
as part of rehabilitation:
– Cardiovascular exercise—many post-AHSCT patients have
reduced aerobic capacity and decreased physical activity.
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Physical activity can restore exercise tolerance and improve
function in patients after AHSCT (60).
– Progressive strengthening training can improve walking and
balance but should be carefully prescribed for individual
patients (53)
– Stretching programme as appropriate (55)
– Positioning and seating
– Spasticity management—commenced or continued
with specific exercises, medication, and splinting as
appropriate (35)
– Handling, facilitation, and specific exercise techniques for
postural realignment
– Mobility progression (35)
– Balance exercises (35)
– Functional task practice
– Swallow guidance (35)
– Communication strategies (35)
– Cognitive rehabilitation (35, 57, 58)
– Fatigue management—please note that graded physical
therapy has been shown to be effective in minimizing post-
HSCT fatigue (61)
– Pain management (35).
Intensity
During this phase, the patients need to be seen every day
by a physiotherapist to ensure that their respiratory function
is monitored and optimized and their physical function is
assessed as well as receiving rehabilitation specific to their
needs. Each patient will respond and react differently to the
transplant process so each rehabilitation package is bespoke.
Regular occupational therapy input is also required to ensure
that independent function is optimized and speech and language
therapy is provided as required.
REHABILITATION DURING PHASE 3:
SUB-ACUTE REHABILITATION
Following the transplant and when medically stable, the
individual should receive a period of intense inpatient
or outpatient rehabilitation to optimize physical fitness,
independence, and the outcome of the transplant. The timing
of this will depend on the patient. This will likely be 8 weeks
following the transplant, as prior to this, patients will be too
weak to fully participate and are at the highest risk of EBV/CMV
reactivation. Even with neutrophil recovery, the immune system
remains suppressed for several months and patients may need
readmission for infections and other complications. Therapists
and patients also need to be aware that there is a risk of “late
effects” associated with AHSCT. These may be the result of
the transplant regimen and altered post-transplant immune
reconstitution, but may also be driven by pre-treatment of the
underlying neurological disease (19).
The rehabilitation in this phase should be aimed at
treating both the neurological presentation and addressing the
neuromuscular weakness and other disabilities now that the
active inflammation has subsided.
Rehabilitation should include a full assessment and a
treatment programme as above and should aim to further
progress the patient. Therapy should consider cardiovascular
workout equipment as well as the use of neuro-technologies
where possible to optimize the effects of the AHSCT. Neuro-
technology enables repetitive task practice. More evidence is
emerging with regards to their benefits in neuro-rehabilitation
(56). Neuro-technology can include the use of robotic gait
training, upper limb devices, strength training, and balance
devices as well as functional electrical stimulation and virtual
rehabilitation (56). Care should always be taken to tailor these
interventions to the individual patient and to monitor the impact
of these technologies as our understanding of the long term
impacts remain unclear.
Overall rehabilitation should follow a biopsychosocial, multi-
disciplinary model with the patient having an allocated
key worker, accessing the health care professionals required
with a structured rehabilitation approach including access to
groups and rehabilitation assistance sessions where appropriate.
Utilizing a patient centered approach, patients and their carers
should be involved with their goal setting. There should also be
family meetings if required and opportunities for education to
fully engage the patient in their rehabilitation. Following a self-
management and self-care approach will ensure motivation, self-
efficacy and the sustainability of behavior change once the patient
has been discharged from formal rehabilitation.
Intensity
The rehabilitation programme provided in this phase should be
intensive. The intensity will vary depending on the patient and
their pre-morbid and post-transplant presentation. For active
individuals who tolerated the transplant procedure well, up to 4 h
of therapy intervention could be received in a typical working
day with input from physiotherapy, occupational therapy, speech
and language therapy, and psychology as appropriate. Therapy
groups can be considered providing immune status is taken
into account.
Advice and Information
Manual handling advice as well as seating and positioning
programmes should be reviewed and any changes communicated
as appropriate. As well as their therapy sessions, patients should
be provided with exercise programmes to complete in their
own time as part of their self-management programme. Patients
should also be provided with advice regarding rest periods and
fatigue management. The discharge planning and links into the
community are made at this time. This includes exploring any
on-going community support and return to work programmes.




This phase of rehabilitation occurs when the individual has
been discharged home. Therapists and individuals need to be
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aware of late-effects of the AHSCT. A fever episode might cause
deterioration in function but patients should be made aware
that such conditions are usually fully reversible. The focus of
rehabilitation during this phase is a continuum of the inpatient
goals within their normal home environment, integrating the
patient back into their home life and promoting independence.
It is important that patients continue with their individualized
rehabilitation programmes and progress their mobility and
independence as able.
Returning to work in a timely manner is important for
this patient group as many are in employment and may have
dependants. Patients are generally not encouraged to return to
work until 3 months post-transplant due to infection risks and in
some cases delayed up until 6 months post-transplant depending
on immune recovery. When and as appropriate, patients should
be referred to appropriate vocational rehabilitation services for
support. Specialist occupational therapists are crucial to carry
out pre-employment physical and functional testing and liaising
with the patient and their employer about returning to work
(62). A specific return to work programme should be designed
for the patient and progression monitored. Education of the
employer is important as is linking into occupational health
departments (62).
Advice and Information
It is important that on-going support and guidance is available
after the patient has returned home. This may require referrals
to appropriate community-based teams including therapy teams,
specialists (e.g., continence, sexual function, tissue viability)
or social services. If appropriate, carers and family members
should also be provided with advice and education to assist
the individual going home. This may include advice on manual
handling including the use of equipment, positioning, seating,
and nutritional or feeding advice.
COMPREHENSIVE REVIEW
Regaining neurological function can continue in the first couple
of years following AHSCT and it is important to optimize this
period of time with a tailored, comprehensive rehabilitation
programme. Patients who have undergone AHSCT should have
a comprehensive review of all aspects of their care at least once
a year, which needs to be carried out by healthcare professionals
with expertise in MS and its complications. The review process
and follow up treatments must be individually tailored to need.
It may result in onward referral for further specialist support
e.g., spasticity management, orthotics or specialist equipment
available as required. Hydrotherapy can be considered providing
immune status is taken into account by transplant physician and
specialist hydrotherapist.
CONCLUSIONS
The consensus recommendations are summarized in Table 1.
Rehabilitation should be considered at each stage of the pathway
on an individualized basis via a proper MDT assessment, with
the aim of preventing secondary problems, reducing length of
TABLE 1 | Recommendations (all consensus).
• All patients with MS undergoing AHSCT should be considered for pre-
habilitation before and rehabilitation following the procedure. Referrals should
be made early so rehabilitation can be delivered at the optimal time.
• Care should be provided with a co-ordinated multidisciplinary team (MDT)
approach with a core and an extended team, who facilitate referral, assessment,
and delivery of rehabilitation throughout the four phases of the pathway.
• Rehabilitation should be goal directed and patient centered and underpinned
by principles of self-management and self-care.
• Rehabilitation for patients with AHSCT should be delivered at 4 phases during
the pathway as detailed.
• All individuals receiving AHSCT should be provided with appropriate advice
and support about the process and the rehabilitation available to them.
Advice leaflets are recommended to guide on exercise, nutrition, and any
necessary lifestyle changes. If appropriate, carers and family members should
also be provided with advice and education to assist the individual. Specialist
consultation may be necessary in some cases.
• Prior to the transplant, baseline level of impairment, function and participation
should be ascertained through a formal MDT assessment process. Risk factors
for potential deterioration should be identified. Following the assessment, carers
including nursing staff and family should be provided with manual handling
advice to facilitate safe transfers and mobility whilst encouraging independence.
• A rehabilitation plan should be tailored to patients’ symptoms and goals.
Rehabilitation provided at each stage of the pathway will be dependent upon
the clinical presentation. A series of validated outcome measures will be taken
at key points throughout the patient’s journey to monitor any change.
• Validated and reliable standardized assessment tools and outcome measures
should be recorded routinely to monitor any change.
• Infection control measures and other precautions appropriate to the stage of
AHSCT (such as thrombocytopenia) should be followed.
• All MS patients who have received AHSCT should have a comprehensive
review of all aspects of their care at least once a year, carried out by
healthcare professionals with expertise in MS working as part of the extended
MDT. Therapists need to be aware of “late-effects” of AHSCT as well as the
potential for relapse and progression of MS.
TABLE 2 | Future health research questions (consensus).
• Will rehabilitation in the AHSCT pathway result in further neurological
improvement and long-term outcome?
• Should a rehabilitation specialist be routinely part of the MDT to coordinate
the rehabilitation and ensure outcome measures are obtained throughout the
AHSCT pathway?
• What are the best outcome measures to use in patients with MS undergoing
AHSCT? Can specific outcome measures be developed for use with MS
patients receiving AHSCT?
• When is the optimal time to start rehabilitation in patients undergoing AHSCT?
Does pre-habilitation have a role in AHSCT for patients with MS?
• Should rehabilitation be provided to patients whilst in isolation, when they are
most heavily immunosuppressed? If so, to what intensity?
• Can length of hospital stay post-transplant be reduced?
• Following discharge, should patients be referred into an intense sub-acute
rehabilitation pathway either as an outpatient or into a step-down residential
rehabilitation setting?
hospital stay and maximizing recovery and long-term outcomes.
There is also potential to reduce long-term care costs. The lack of
evidence-base to support the benefits (and risks) of rehabilitation
in MS patients undergoing AHSCT is highlighted and further
research is warranted. Table 2 summarises the future health
research questions. The proposed framework for rehabilitation
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can be factored into clinical trials and future practice can be
refined to reflect emerging evidence.
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